DOLOMITE - Safety and effectiveness of DTG use in pregnancy


A multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women


Indication:  HIV positive women receiving DTG (at least 200 starting or on DTG in the first trimester)


Phase: IV


Countries:  Canada, Europe


Status: Actively recruiting

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK



Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019